

Disposition of the cultural item in this notice may occur on or after June 18, 2026. If competing claims for disposition are received, the Chugach National Forest must determine the most appropriate claimant prior to disposition. Claims for joint disposition of the cultural item are considered a single claim and not competing claims. The Chugach National Forest is responsible for sending a copy of this notice to the lineal descendants, Indian Tribes, and Native Hawaiian organizations identified in this notice and to any other consulting parties.

Authority: Native American Graves Protection and Repatriation Act, 25 U.S.C. 3002, and the implementing regulations, 43 CFR 10.7.

Dated: May 12, 2026.

Melanie O'Brien,

Manager, National NAGPRA Program.

[FR Doc. 2026–10027 Filed 5–18–26; 8:45 am]

BILLING CODE 4312–52–P

INTERNATIONAL TRADE COMMISSION

[Investigation Nos. 731–TA–776–779 (Fifth Review)]

Certain Preserved Mushrooms from Chile, China, India, and Indonesia; Scheduling of Expedited Five-Year Reviews

AGENCY: United States International Trade Commission.

ACTION: Notice.

SUMMARY: The Commission hereby gives notice of the scheduling of expedited reviews pursuant to the Tariff Act of 1930 (“the Act”) to determine whether revocation of the antidumping duty orders on certain preserved mushrooms from Chile, China, India, and Indonesia would be likely to lead to continuation or recurrence of material injury within a reasonably foreseeable time.

DATES: May 8, 2026.

FOR FURTHER INFORMATION CONTACT: Peter Stebbins (202–205–2039), Office of Investigations, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436. Hearing-impaired persons can obtain information on this matter by contacting the Commission’s TDD terminal on 202–205–1810. Persons with mobility impairments who will need special assistance in gaining access to the Commission should contact the Office of the Secretary at 202–205–2000. General information concerning the Commission may also be obtained by accessing its internet server (<https://www.usitc.gov>). The public record for

this proceeding may be viewed on the Commission’s electronic docket (EDIS) at <https://edis.usitc.gov>.

SUPPLEMENTARY INFORMATION:

Background.—On May 8, 2026, the Commission determined that the domestic interested party group response to its notice of institution (91 FR 4622, February 2, 2026) of the subject five-year reviews was adequate and that the respondent interested party group response was inadequate. The Commission did not find any other circumstances that would warrant conducting full reviews.¹ Accordingly, the Commission determined that it would conduct expedited reviews pursuant to section 751(c)(3) of the Act (19 U.S.C. 1675(c)(3)).²

For further information concerning the conduct of these reviews and rules of general application, consult the Commission’s Rules of Practice and Procedure, part 201, subparts A and B (19 CFR part 201), and part 207, subparts A, D, E, and F (19 CFR part 207).

Staff report.—A staff report containing information concerning the subject matter of the reviews has been placed in the nonpublic record, and will be made available to persons on the Administrative Protective Order service list for these reviews on June 16, 2026. A public version will be issued thereafter, pursuant to § 207.62(d)(4) of the Commission’s rules.

Written submissions.—As provided in § 207.62(d) of the Commission’s rules, interested parties that are parties to the reviews and that have provided individually adequate responses to the notice of institution,³ and any party other than an interested party to the reviews may file written comments with the Secretary on what determination the Commission should reach in the reviews. Comments are due on or before 5:15 p.m. on June 23, 2026, and may not contain new factual information. Any person that is neither a party to the five-year reviews nor an interested party may submit a brief written statement (which shall not contain any new factual information) pertinent to the reviews by June 23, 2026. However, should the Department of Commerce

¹ A record of the Commissioners’ votes, the Commission’s statement on adequacy, and any individual Commissioner’s statements will be available from the Office of the Secretary and at the Commission’s website.

² Commissioner David S. Johanson voted to conduct full reviews.

³ The Commission has found the response submitted on behalf of Giorgio Foods, Inc. and L.K. Bowman Co., a division of Hanover Foods Corporation, to be individually adequate. Comments from other interested parties will not be accepted (see 19 CFR 207.62(d)(2)).

(“Commerce”) extend the time limit for its completion of the final results of its reviews, the deadline for comments (which may not contain new factual information) on Commerce’s final results is three business days after the issuance of Commerce’s results. If comments contain business proprietary information (BPI), they must conform with the requirements of §§ 201.6, 207.3, and 207.7 of the Commission’s rules. The Commission’s *Handbook on Filing Procedures*, available on the Commission’s website at https://www.usitc.gov/documents/handbook_on_filing_procedures.pdf, elaborates upon the Commission’s procedures with respect to filings.

In accordance with §§ 201.16(c) and 207.3 of the rules, each document filed by a party to the reviews must be served on all other parties to the reviews (as identified by either the public or BPI service list), and a certificate of service must be timely filed. The Secretary will not accept a document for filing without a certificate of service.

Determination.—The Commission has determined these reviews are extraordinarily complicated and therefore has determined to exercise its authority to extend the review period by up to 90 days pursuant to 19 U.S.C. 1675(c)(5)(B).

Authority: These reviews are being conducted under authority of title VII of the Tariff Act of 1930; this notice is published pursuant to § 207.62 of the Commission’s rules.

By order of the Commission.

Issued: May 15, 2026.

Sharon Bellamy,

Supervisory Hearings and Information Officer.

[FR Doc. 2026–09984 Filed 5–18–26; 8:45 am]

BILLING CODE 7020–02–P

INTERNATIONAL TRADE COMMISSION

[Investigation Nos. 701–TA–463 and 731–TA–1159 (Third Review)]

Oil Country Tubular Goods From China; Determinations

On the basis of the record¹ developed in the subject five-year reviews, the United States International Trade Commission (“Commission”) determines, pursuant to the Tariff Act of 1930 (“the Act”), that revocation of the antidumping and countervailing duty orders on oil country tubular goods from China would be likely to lead to

¹ The record is defined in § 207.2(f) of the Commission’s Rules of Practice and Procedure (19 CFR 207.2(f)).

continuation or recurrence of material injury to an industry in the United States within a reasonably foreseeable time.

Background

The Commission instituted these reviews on November 3, 2025 (90 FR 55167, December 1, 2025) and determined on March 6, 2026 that it would conduct expedited reviews (91 FR 18004, April 9, 2026).

The Commission made these determinations pursuant to section 751(c) of the Act (19 U.S.C. 1675(c)). It completed and filed its determinations in these reviews on May 15, 2026. The views of the Commission are contained in USITC Publication 5739 (May 2026), entitled *Oil Country Tubular Goods from China: Investigation Nos. 701-TA-463 and 731-TA-1159 (Third Review)*.

By order of the Commission.

Issued: May 15, 2026.

Sharon Bellamy,

Supervisory Hearings and Information Officer.

[FR Doc. 2026-10002 Filed 5-18-26; 8:45 am]

BILLING CODE 7020-02-P

INTERNATIONAL TRADE COMMISSION

[Investigation No. 337-TA-1447]

Certain Drug Products Containing C-Type Natriuretic Peptide Variants, and Components Thereof; Notice of a Commission Determination Not To Review an Initial Determination Amending the Complaint and Notice of Investigation

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

SUMMARY: Notice is hereby given that the U.S. International Trade Commission (“Commission”) has determined not to review an initial determination (“ID”) (Order No. 45) of the presiding Chief administrative law judge (“Chief ALJ”) granting complainant’s unopposed motion to amend the complaint and notice of investigation to reflect respondent Ascendis Pharma, Inc.’s corporate name change to Ascendis Pharma, LLC.

FOR FURTHER INFORMATION CONTACT: Jonathan D. Link, Esq., Office of the General Counsel, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone (202) 205-3103. Copies of non-confidential documents filed in connection with this investigation may be viewed on the Commission’s electronic docket (EDIS)

at <https://edis.usitc.gov>. For help accessing EDIS, please email EDIS3Help@usitc.gov. General information concerning the Commission may also be obtained by accessing its internet server at <https://www.usitc.gov>. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission’s TDD terminal on (202) 205-1810.

SUPPLEMENTARY INFORMATION: The Commission instituted this investigation on May 8, 2025, based on a complaint filed by BioMarin Pharmaceutical Inc. of Novato, CA (“Complainant”). 90 FR 19532-33 (May 8, 2025). The complaint, as supplemented, alleges violations of section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, in the importation into the United States, the sale for importation, or the sale within the United States after importation of certain drug products containing C-type natriuretic peptide variants and components thereof by reason of infringement of claims 15-20, and 31-48 of RE’267 patent. *Id.* The complaint further alleges that a domestic industry exists. *Id.* The Commission’s notice of investigation named as respondents: Ascendis Pharma, Inc. of Palo Alto, California; Ascendis Pharma A/S of Hellerup, Denmark; Ascendis Pharma Growth Disorders A/S of Hellerup, Denmark (collectively “Ascendis”); and Wacker Biotech GmbH of Jena, Germany. *Id.* The Office of Unfair Import Investigations (“OUII”) is participating in the investigation. *Id.*

On September 12, 2025, the Commission determined not to review Order No. 15 granting Complainant’s motion to amend the complainant and notice of investigation to add Bachem Ag as an additional respondent. *See* Order No. 15 (Aug. 14, 2025), *unreviewed by Comm’n Notice* (Sept. 12, 2025), 90 FR 44843 (Sept. 17, 2025).

On March 23, 2026, the Commission determined not to review an initial determination (Order No. 36) terminating from the investigation claims 15-22, 31, 33, 35-40, 42, 44, and 45-48 of the RE’267 patent, with claims 21-22 having been asserted for domestic industry purposes only. *See* Order No. 36 (Mar. 3, 2026), *unreviewed by Comm’n Notice* (Mar. 23, 2026).

On April 14, 2026, Complainant filed a motion to amend the amended complaint and notice of investigation to reflect respondent Ascendis Pharma, Inc.’s corporate name change to Ascendis Pharma, LLC. No responses to the motion were filed.

On April 27, 2026, the ALJ issued the subject ID (Order No. 45), granting

Complainant’s unopposed motion to amend the amended complaint and notice of investigation. No petitions for review of the ID were filed.

The Commission has determined not to review the subject ID. The notice of investigation is amended to reflect respondent Ascendis Pharma, Inc.’s corporate name change to Ascendis Pharma, LLC.

The Commission vote for this determination took place on May 15, 2026.

The authority for the Commission’s determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in Part 210 of the Commission’s Rules of Practice and Procedure (19 CFR part 210).

By order of the Commission.

Issued: May 15, 2026.

Sharon Bellamy,

Supervisory Hearings and Information Officer.

[FR Doc. 2026-10010 Filed 5-18-26; 8:45 am]

BILLING CODE 7020-02-P

NUCLEAR REGULATORY COMMISSION

[Docket No. M70-7033-ML; ASLBP No. 26-992-01-ML-BD02]

Global Laser Enrichment, LLC; Establishment of Atomic Safety and Licensing Board

Pursuant to the Commission’s regulations, *see, e.g.*, 10 CFR 2.104, 2.105, 2.300, 2.309, 2.313, 2.318, 2.321, notice is hereby given that an Atomic Safety and Licensing Board (Board) is being established to preside over the following proceeding:

GLOBAL LASER ENRICHMENT, LLC (Paducah Laser Enrichment Facility)
Global Laser Enrichment, LLC (GLE) has applied for a license to possess and use special nuclear material for the purpose of constructing and operating a uranium enrichment facility in McCracken County, Kentucky. The requested license would authorize the facility to re-enrich depleted uranium hexafluoride tails and enrich natural-grade uranium hexafluoride to a maximum of 8-weight percent uranium-235 via laser-based isotope separation technology.

Because GLE is seeking authorization to construct a uranium enrichment facility, pursuant to Section 193 of the Atomic Energy Act, as amended (42 U.S.C. 2243), and 10 CFR 70.23a, an uncontested mandatory hearing will be conducted following completion of the NRC staff’s safety evaluation and